“Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer” has been added to your cart. View cart

Article: O.4 SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma

€2.42

SKU: product-article-18262 Category: General

Description
Reviews (0)

Description

O.4 SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma

Reviews

There are no reviews yet.

Be the first to review “Article: O.4 SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma”

Top

Article: O.4 SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma

Description

Reviews

Related products

Article: Highlights in gynaecological cancers

Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma

Article: Highlights in melanoma

Article: INTRODUCTION